These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 11021735)

  • 61. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model.
    Jacquet P; Averbach A; Stuart OA; Chang D; Sugarbaker PH
    Cancer Chemother Pharmacol; 1998; 41(2):147-54. PubMed ID: 9443628
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
    Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Pharmacokinetics and disposition of a new antitumor antibiotic (2''R)-4'-O-tetrahydropyranyladriamycin in rats. Distribution and excretion after multiple administration].
    Tone H; Iguchi H; Shomura T; Komiya I; Nishio M
    Jpn J Antibiot; 1986 Feb; 39(2):629-37. PubMed ID: 3712762
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs.
    Waddle JR; Fine RL; Case BC; Trogdon ML; Tyczkowska K; Frazier D; Page RL
    Cancer Chemother Pharmacol; 1999; 44(1):74-80. PubMed ID: 10367752
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats.
    Asakura E; Nakayama H; Sugie M; Zhao YL; Nadai M; Kitaichi K; Shimizu A; Miyoshi M; Takagi K; Takagi K; Hasegawa T
    Eur J Pharmacol; 2004 Jan; 484(2-3):333-9. PubMed ID: 14744620
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
    Licata S; Saponiero A; Mordente A; Minotti G
    Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of coenzyme Q10 on the disposition of doxorubicin in rats.
    Zhou Q; Chowbay B
    Eur J Drug Metab Pharmacokinet; 2002; 27(3):185-92. PubMed ID: 12365200
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.
    Mross K; Maessen P; van der Vijgh WJ; Gall H; Boven E; Pinedo HM
    J Clin Oncol; 1988 Mar; 6(3):517-26. PubMed ID: 3162516
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Protective effect of 23-hydroxybetulinic acid on doxorubicin-induced cardiotoxicity: a correlation with the inhibition of carbonyl reductase-mediated metabolism.
    Zhou F; Hao G; Zhang J; Zheng Y; Wu X; Hao K; Niu F; Luo D; Sun Y; Wu L; Ye W; Wang G
    Br J Pharmacol; 2015 Dec; 172(23):5690-703. PubMed ID: 25363561
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.
    Hartman N; Basseches PJ; Powis G
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):11-5. PubMed ID: 6819097
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of doxorubicin on rats that received toxic and carcinogenic benzo(a)pyrene.
    Cosan D; Basaran A; Gunes HV; Degirmenci I; Aral E
    Folia Histochem Cytobiol; 2008; 46(3):367-72. PubMed ID: 19056542
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
    Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
    J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit.
    Cusack BJ; Tesnohlidek DA; Loseke VL; Vestal RE; Brenner DE; Olson RD
    Cancer Chemother Pharmacol; 1988; 22(4):294-8. PubMed ID: 3168142
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The endothelin receptor blocker bosentan inhibits doxorubicin-induced cardiomyopathy.
    Bien S; Riad A; Ritter CA; Gratz M; Olshausen F; Westermann D; Grube M; Krieg T; Ciecholewski S; Felix SB; Staudt A; Schultheiss HP; Ewert R; Völker U; Tschöpe C; Kroemer HK
    Cancer Res; 2007 Nov; 67(21):10428-35. PubMed ID: 17974986
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of tamoxifen on the pharmacokinetics of theophylline in rats.
    Poisson D; Dupuis A; Breteau M; Bouquet S; Poterre M; Couet W
    J Pharm Pharmacol; 1997 Jan; 49(1):40-2. PubMed ID: 9120768
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma.
    El-Yazigi A; Berry J; Ezzat A; Wahab FA
    Ther Drug Monit; 1997 Dec; 19(6):632-6. PubMed ID: 9421103
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans.
    Robert J; Armand JP; Huet S; Klink-Alakl M; Recondo G; Hurteloup P
    J Clin Oncol; 1992 Jul; 10(7):1183-90. PubMed ID: 1607922
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment.
    Gziri MM; Pokreisz P; De Vos R; Verbeken E; Debiève F; Mertens L; Janssens SP; Amant F
    J Pharmacol Exp Ther; 2013 Sep; 346(3):362-9. PubMed ID: 23792410
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acute dosage with dexrazoxane, but not doxorubicin, is associated with increased rates of hepatic protein synthesis in vivo.
    Zima T; Tesar V; Sherwood R; Sood A; Au LC; Richardson PJ; Preedy VR
    Toxicol Pathol; 2001; 29(6):591-9. PubMed ID: 11794374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.